Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christian A. Powers"'
Autor:
Stephen R. Russell, Arlene V. Drack, Artur V. Cideciyan, Samuel G. Jacobson, Bart P. Leroy, Caroline Van Cauwenbergh, Allen C. Ho, Alina V. Dumitrescu, Ian C. Han, Mitchell Martin, Wanda L. Pfeifer, Elliott H. Sohn, Jean Walshire, Alexandra V. Garafalo, Arun K. Krishnan, Christian A. Powers, Alexander Sumaroka, Alejandro J. Roman, Eva Vanhonsebrouck, Eltanara Jones, Fanny Nerinckx, Julie De Zaeytijd, Rob W. J. Collin, Carel Hoyng, Peter Adamson, Michael E. Cheetham, Michael R. Schwartz, Wilhelmina den Hollander, Friedrich Asmus, Gerard Platenburg, David Rodman, Aniz Girach
Publikováno v:
Nature Medicine, 28, 1014-1021
NATURE MEDICINE
Nature Medicine, 28, 5, pp. 1014-1021
NATURE MEDICINE
Nature Medicine, 28, 5, pp. 1014-1021
CEP290-associated Leber congenital amaurosis type 10 (LCA10) is a retinal disease resulting in childhood blindness. Sepofarsen is an RNA antisense oligonucleotide targeting the c.2991+1655A>G variant in the CEP290 gene to treat LCA10. In this open-la
Autor:
Alexandra V. Garafalo, Allen C. Ho, Alina V. Dumitrescu, David M. Rodman, Rob W.J. Collin, Carel B. Hoyng, Wanda L. Pfeifer, Mitchell Martin, Arun kumar Krishnan, Julie De Zaeytijd, Bart P. Leroy, Eva Vanhonsebrouck, Aniz Girach, Alejandro J. Roman, Stephen R. Russell, Wilhelmina den Hollander, Gerard Platenburg, Ian C. Han, Fanny Nerinckx, Arlene V. Drack, Christian A. Powers, Friedrich Asmus, Jean Walshire, Samuel G. Jacobson, Caroline Van Cauwenbergh, Elliott H. Sohn, Artur V. Cideciyan, Eltanara A Jones, Michael R. Schwartz, Michael E. Cheetham, Peter Adamson, Alexander Sumaroka
Publikováno v:
SSRN Electronic Journal.
Background: Sepofarsen is an RNA antisense oligonucleotide (AON) targeting the common c.2991+1655A>G mutation in the CEP290 gene to treat Leber congenital amaurosis type 10 (LCA10), a condition with severe childhood-onset vision loss or blindness. Me
Autor:
Alejandro J, Roman, Christian A, Powers, Evelyn P, Semenov, Rebecca, Sheplock, Valeryia, Aksianiuk, Robert C, Russell, Alexander, Sumaroka, Alexandra V, Garafalo, Artur V, Cideciyan, Samuel G, Jacobson
Publikováno v:
International Journal of Molecular Sciences
Recessively-inherited NR2E3 gene mutations cause an unusual retinopathy with abnormally-increased short-wavelength sensitive cone (S-cone) function, in addition to reduced rod and long/middle-wavelength sensitive cone (L/M-cone) function. Progress to
Autor:
Malgorzata Swider, Brianna Lisi, Jason Charng, Bhavya S. Iyer, Vivian Wu, Christian A. Powers, Artur V. Cideciyan, Alexander Sumaroka, Samuel G. Jacobson
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 21, p 5344 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 21
International Journal of Molecular Sciences
Volume 20
Issue 21
Gene therapy for adRP due to RHO mutations was recently shown to prevent photoreceptor death in a canine model of Class B disease. Among translational steps to be taken, one is to determine a method to detect efficacy in a human clinical trial. The r
Autor:
Alexandra V. Garafalo, Alexander Sumaroka, Christian A. Powers, Samuel G. Jacobson, Alejandro J. Roman, Evelyn P. Semenov, Artur V. Cideciyan, Robert C. Russell, Rebecca Sheplock, Valeryia Aksianiuk
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 10, p 2497 (2019)
Recessively-inherited NR2E3 gene mutations cause an unusual retinopathy with abnormally-increased short-wavelength sensitive cone (S-cone) function, in addition to reduced rod and long/middle-wavelength sensitive cone (L/M-cone) function. Progress to
Autor:
Christian A. Powers, Samantha L. Savitch, Jeffrey C. Thompson, Erica L. Carpenter, Stephanie S. Yee, Michael Feldman, Anil Vachani, Steve Gross, Chandra Rao, Lauren Gebrian, Ryan Fan, Gordon H. Yu
Publikováno v:
Cancer Research. 77:3736-3736
Introduction: Malignant pleural effusions (MPE) occur as a frequent complication of advanced non-small cell lung cancer (NSCLC), and denote a poor prognosis. Cytological evaluation of MPEs has a sensitivity of only 40-60%. The CellSearch technology (